Arcus Biosciences, Inc. has completed a public offering of its common stock, raising approximately $269.7 million in gross proceeds. The company entered into an underwriting agreement on October 21, 2026, with Jefferies LLC, Leerink Partners LLC, and TD Securities (USA) LLC as representatives of the underwriters.
The offering involved the sale of 14,285,715 shares of common stock at a public offering price of $17.50 per share. Additionally, the underwriters were granted an option to purchase up to an additional 2,142,857 shares at the same public price, less discounts and commissions. This option was exercised in full.
The closing of the offering took place on October 23, 2026. At that time, the company sold a total of 16,428,572 shares of common stock. The shares were sold to the underwriters at a price of $16.45 per share. After deducting underwriting discounts and commissions and estimated offering expenses, Arcus received net proceeds of approximately $269.7 million.
The transaction was conducted pursuant to an effective registration statement on Form S-3 (Registration Statement No. 333-293750) and accompanying prospectus supplements filed with the Securities and Exchange Commission. The underwriting agreement and related legal opinions are attached as exhibits to the filing.
